Piramal Pharma Analyst Review May 2026

This Piramal Pharma analyst review for May 2026 covers the key data investors need for PPLPHARMA at its current price of Rs 172.26. Piramal Pharma (NSE: PPLPHARMA) is a diversified pharma company with a market capitalisation of approximately Rs 19,000 crore, operating CDMO, complex hospital generics, and India consumer healthcare businesses. The analyst consensus target of Rs 280 implies meaningful upside, and this Piramal Pharma analyst review examines technical levels, business performance, valuation, and key risks for PPLPHARMA through FY27.

Click Here – Get Free Investment Predictions

Piramal Pharma Company Snapshot May 2026

Piramal Pharma’s CDMO division (PharmaLex, inhalation, sterile injectables) serves global innovator pharma. The Littleford India consumer healthcare business (Lacto Calamine, Saridon) adds branded OTC revenue. The table below summarises the key data referenced in this Piramal Pharma analyst review.

Parameter	Value
NSE Ticker	PPLPHARMA
Sector	Pharmaceuticals – CDMO and OTC
CMP (May 2026)	Rs 172.26
52 Week High	Rs 226.00
52 Week Low	Rs 132.30
Market Cap	Rs 19,000 Crore
Trailing P/E	NAx
Analyst Consensus Target	Rs 280
Bull Case Target	Rs 340
Bear Case Target	Rs 180

Analyst Insight in This Piramal Pharma Analyst Review

Associate Director Kunal Singla suggests watching Piramal Pharma closely in May 2026. At Rs 172.26, Kunal Singla flags Pharmaceuticals – CDMO and OTC sector dynamics as the primary driver for PPLPHARMA’s near-term price action. He notes support in the Rs 135 to Rs 164 zone and flags any sustained close above Rs 183 as a positive signal. Kunal Singla’s perspective on Piramal Pharma adds professional analysis to this Piramal Pharma analyst review and is not a buy recommendation.

Technical Analysis in This Piramal Pharma Analyst Review

At Rs 172.26, PPLPHARMA is trading within its 52-week band of Rs 132.30 to Rs 226.00. The current position relative to the 52-week high and low is the first layer of technical context for any entry or exit decision. Momentum indicators including the 14-day RSI, MACD crossover, and volume trends are useful secondary signals to monitor alongside the Nifty 50 direction.

Near-term support is identified in the Rs 135 to Rs 164 band while resistance is seen in the Rs 183 to Rs 226 zone. A sustained move above Rs 183 could open the path toward the analyst consensus target of Rs 280 as identified in this Piramal Pharma analyst review.

Screen the best stocks on the Univest Screener.

Key Support and Resistance Levels

• Support Zone: Rs 135 to Rs 164 – investors tracking this Piramal Pharma analyst review should watch for stabilisation or a bounce in this range as a potential accumulation signal for PPLPHARMA.
• Resistance Zone: Rs 183 to Rs 226 – a sustained close above Rs 183 would be a positive breakout signal worth flagging in this Piramal Pharma analyst review.
• Medium-Term Target: The analyst consensus of Rs 280 represents the base-case upside scenario in this Piramal Pharma analyst review.

Business Segment Analysis

Pharma CDMO (Inhalation, Sterile Injectables)

This is the primary revenue and margin driver for Piramal Pharma, directly supporting the earnings trajectory toward the consensus target of Rs 280.

Complex Hospital Generics (US and Global Markets)

This segment adds scale and diversification to Piramal Pharma’s business model and is a meaningful EPS contributor through FY27 and FY28.

India Consumer Healthcare (Lacto Calamine, Saridon)

This represents the medium-term growth frontier for Piramal Pharma and a key re-rating catalyst for the stock over the next 12 to 24 months.

Valuation in This Piramal Pharma Analyst Review

At Rs 172.26, Piramal Pharma trades at a trailing P/E of NAx. This Piramal Pharma analyst review presents three scenarios: a bull case of Rs 340 on strong earnings delivery, a base case of Rs 280 at analyst consensus, and a bear case of Rs 180 if macro headwinds persist. Q1 FY27 results will be the first key checkpoint for this Piramal Pharma analyst review.

Scenario	Target Price	Key Condition
Bull Case	Rs 340	Strong earnings delivery and sector re-rating
Base Case (Consensus)	Rs 280	Moderate growth, analyst consensus estimate
Bear Case	Rs 180	Earnings miss or macro headwinds

Trade Outlook for Piramal Pharma

Based on the technical and fundamental analysis in this Piramal Pharma analyst review, investors might watch PPLPHARMA near the support zone of Rs 135 to Rs 164 for potential opportunities. A flag above Rs 183 could suggest improving momentum toward Rs 280. This article uses watch-and-flag language only and does not constitute a trade recommendation.

Key Risks for Piramal Pharma in FY27

A well-rounded Piramal Pharma analyst review must assess downside risks. Key risks for Piramal Pharma include a macro slowdown affecting Pharmaceuticals – CDMO and OTC sector demand, input cost or regulatory headwinds compressing margins, continued FII selling from Indian equities, and earnings estimate downgrades if Q1 FY27 guidance disappoints. Market conditions may change rapidly. This analysis is not financial advice; investors should perform their own due diligence before investing in PPLPHARMA.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Conclusion: Piramal Pharma Analyst Review Verdict for 2026

This Piramal Pharma analyst review concludes that at Rs 172.26, PPLPHARMA offers a defined risk-reward with a consensus target of Rs 280. The 52-week range of Rs 132.30 to Rs 226.00 provides context on the current entry point. Use this Piramal Pharma analyst review as a research starting point and consult a SEBI-registered financial advisor before making any investment decisions on PPLPHARMA.

Frequently Asked Questions: Piramal Pharma Analyst Review 2026

What is the analyst target for Piramal Pharma in 2026?

The analyst consensus target is Rs 280, with a bull case of Rs 340 and a bear case of Rs 180. This Piramal Pharma analyst review recommends monitoring Q1 FY27 earnings for confirmation.

Is Piramal Pharma a good investment at Rs 172.26?

At Rs 172.26 with a P/E of NAx and a consensus target of Rs 280, this Piramal Pharma analyst review is constructive for medium to long-term investors in the Pharmaceuticals – CDMO and OTC sector. Always consult a SEBI-registered advisor before investing.

What is Piramal Pharma’s 52-week high and low?

The 52-week high is Rs 226.00 and the 52-week low is Rs 132.30. At Rs 172.26, PPLPHARMA is positioned within this range as noted in this Piramal Pharma analyst review.

What are the key risks for Piramal Pharma?

Key risks include macro slowdown, input cost pressures, FII selling, and regulatory changes in the Pharmaceuticals – CDMO and OTC sector as assessed in this Piramal Pharma analyst review.

Where can I track live data for Piramal Pharma?

Track Piramal Pharma’s live price and analyst targets on the Univest Screener alongside professional financial advice to complement this Piramal Pharma analyst review.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice. Please consult a SEBI-registered financial advisor before making any investment decisions.